Literature DB >> 1630075

Effects of monohydroxylated fatty acids on arterial smooth muscle cell properties.

I Ramboer1, P Blin, G Lacape, D Daret, J M Lamaziere, J Larrue.   

Abstract

The hydroxylated derivatives of polyunsaturated fatty acids may be potent modulators of basic biological responses involved in pathological processes, including atherosclerosis. The object of the present investigation was to study the effects of monohydroxylated fatty acids (namely 12-HETE) on the properties of aortic smooth muscle cells (SMC) in culture. The changes in cell expression of differentiation antigen alpha-SM actin and 2P1A2 was followed by computerized morphometry, using specific monoclonal antibodies and the activation of cells by measuring cell motility. In addition, intracellular [Ca2+]i mobilization and IP3 formation were studied. Finally, the metabolic routes of monohydroxylated compounds and their effects on PGI2 secretion were reported. The results demonstrate that 12-HETE is able to stimulate the phenotypic modulation. PGI2 production and motility of arterial SMCs, despite any detectable activity in increasing [Ca2+]i or IP3 formation. By contrast with parent compounds 15-HETE and 13-HODE, which appear as potent prodifferentiating molecules, 12-HETE is specifically metabolized via a 10-11 reductase pathway in addition to the classical beta-oxidation pathway. Taken together, our results suggest that cellular metabolism of 12-HETE, produced by platelets in the vicinity of the arterial intima, and also by cells present inside the atherosclerotic intima, or associated with modified LDL may play a key role in the atherosclerotic process.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1630075

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  1 in total

1.  Hydroxyoctadecadienoic acids: novel regulators of macrophage differentiation and atherogenesis.

Authors:  Venkat Vangaveti; Bernhard T Baune; R Lee Kennedy
Journal:  Ther Adv Endocrinol Metab       Date:  2010-04       Impact factor: 3.565

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.